SAN FRANCISCO–Maintenance therapy with erlotinib (Tarceva) in patients with non-small-cell lung cancer following chemotherapy provided a statistically significant improvement in survival, according to results from the SATURN trial.
Ed Susman
Advertisement
Articles by Ed Susman
Advertisement
Latest Updated Articles
- Erlotinib maintenance therapy in lung cancer sows survival benefit
Published: August 24th 2009 | Updated:
